{"id":"W4412820579","doi":"10.1038/s41408-025-01329-2","title":"Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Sanofi; Kyowa Hakko Kirin; Cilag; Italfarmaco; Seagen; Celltrion; Pfizer; Incyte; BeiGene; Astex Pharmaceuticals; Kite Pharma; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; Leukemia and Lymphoma Society; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen","keywords":"Brentuximab vedotin; Oncology; Medicine; Internal medicine; Chemotherapy; Subgroup analysis; Anaplastic large-cell lymphoma; Lymphoma; Front line; Clinical trial; Hodgkin lymphoma; Meta-analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001815652,0.0008799767,0.002317659,0.0004002004,0.0002605799,0.001078647,0.0006135646,0.0007007979,0.002047323],"category_scores_gemma":[0.001810969,0.0002988162,0.004903593,0.0005199502,0.0003245877,0.0008444452,0.0005222166,0.001720247,0.0002675963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007103138,"about_ca_system_score_gemma":0.0005381433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001598574,"about_ca_topic_score_gemma":0.004860265,"domain_scores_codex":[0.9992392,0.0003420594,0.00007054258,0.0001360891,0.00007427371,0.0001378355],"domain_scores_gemma":[0.9993452,0.0001854499,0.0001945386,0.0001190192,0.00003938172,0.0001162629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8500725,0.001160267,0.04415384,0.002982973,0.04996727,0.0003014584,0.0001354913,0.002933426,0.00292837,0.000410091,0.003550738,0.04140364],"study_design_scores_gemma":[0.5076101,0.07321423,0.2912284,0.001305011,0.1013663,0.0007322098,0.0005500387,0.008154972,0.002062501,0.003703996,0.009901511,0.0001707757],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768788,0.0172036,0.000603397,0.0004298971,0.0003659376,0.0005308275,0.001980992,0.00003830871,0.001968158],"genre_scores_gemma":[0.9940035,0.001992711,0.0003534001,0.0003631287,0.0002227168,0.0003370854,0.001850728,0.00001323765,0.0008634358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002317659,"threshold_uncertainty_score":0.009602189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01372082772655073,"score_gpt":0.2857180315438789,"score_spread":0.2719972038173281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}